Effect of therapy with rosuvastatin on lipid spectrum, factors of inflammation and endothelial function in patients with ischemic heart disease

Kardiologiya

Volumn 46, Issue 5, 2006, Pages 4-8

  Sergienko, I V ^a   Samoilenko, E Yu ^a   Masenko, V P ^a   Ezhov, M V ^a   Sumarokov, A B ^a   Tkachev, G A ^a   Pogorelova, O A ^a   Balakhonova, T V ^a   Naumov, V G ^a  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

Ischemic heart disease; Rosuvastatin

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PYRIMIDINE DERIVATIVE; ROSUVASTATIN; SULFONAMIDE;

ARTICLE; BLOOD; BRACHIAL ARTERY; COMPARATIVE STUDY; DOPPLER FLOWMETRY; DRUG EFFECT; ECHOGRAPHY; FOLLOW UP; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASODILATATION;

BIOLOGICAL MARKERS; BRACHIAL ARTERY; C-REACTIVE PROTEIN; ENDOTHELIUM, VASCULAR; FLUOROBENZENES; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; LIPIDS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER; VASODILATION;

EID: 33747171728     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Schuster H., Fox J. C. Investigating cardiovascular risk reduction-the Rosuvastatin GALAXY Programme. Exp Opin Pharmacother 2004;5:5:1187-1200.
2. Ridker P.M., Rifai N., Stampfer M.J., Hennekens C.H. Plasma concentration of Interleukin-6 and the Risk of Future Myocardial Infarction Among Apparently Healthy Men. Circulation 2000;101:15:1767-1772.
3. Sager P., Melani L., Lipka L. et al. for the Ezetimib Study Group. Effect of coadministration of Ezetimibe and Simvastatin on High-Sensivity C-Reactive Protein. Am J Cardiol 2003;92:12:1414-1418.
4. Wahre T., Yundestat A., Smith C. et al. Increased Expression of Interleukin-1 in Coronary Artery Disease With Downregulatory Effects of HMG-CoA Reductase Inhibitors. Circulation 2004;109:16:1966-1972.
5. Schonebeck U., Varo N., Libby P. et al. Soluble CD40L and cardiovascular risk in women. Circulation 2001;104:2266-2268.
6. Kinlay S., Schwartz G., Olsson N. et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in Myocardial Ischemia Reduction and Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 2004;110:386-391.
7. Pruefer D., Makowski J., Schnell M. et al. Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation 2002;106:2104-2110.
8. Ridker P.M., Rifai N., Pfeffer M.A. et al. Long-term effects of pravastatin on plasma-concentrations of C-reactive protein. Circulation 1999;100:230-235.
9. Pahan K., Sheikh F.G., Namboodiri A.M., Singh I. Lovastatin and phenyl-acetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997;100:2671-2679.
10. Aengevaeren W.R. Beyond lipids the role of the endothelium in coronary artery disease. Atherosclerosis 1999;147:Suppl 1:S11-S16.
11. Taddei S., Virdis A., Mattei P. et al. Endothelium-dependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension. J Cardiovasc Pharmacol 1992;20:Suppl 12:8193-8195.
12. Treasure C.B., Klein J.L., Weintraub W.S. et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-487.
13. Masumoto A., Hirooka Y., Hironaga K. et al. Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin). Am J Cardiol 2001;88:1291-1294.
14. Gibbons G.H. Cardioprotective mechanisms of ACE inhibition. The angiotensin II nitric oxide balance. Drugs 1997;54:Suppl 5:1-11.
15. Shepherd J., Hunninghake D.B., Stein E.A. et al. Safety of rosuvastatin. Am J Cardiol 2004;94:882-888.
16. Blasetto J. W. Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. Am J Cardiol 2003;91:5A:3C-10C.
17. Ridker P.M., Cannon C.P. et al. for PROVE IT-TIMI 22 Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-28.
18. Nissen S.E., Tuzcu E., Schoenhagen P. et al. for REVERSAL Investigators Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease. N Engl J Med 2005;352:1:29-38.
19. Armstrong V.W., Cremer P., Eberle E. et al. The association between serum Lp(a) concentration and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis 1986;62:249-257.
20. Maher V.M.G., Brown B.G. Lipoprotein(a) and coronary heart disease. Curr Opin Lipidol 1995;6:229-235.
21. Brown S.A., Morrisett I.D., Boerwinkle E. et al. The relation of lipoprotein(a) concentrations and apolipoprotein(a) phenotypes with asymptomatic atherosclerosis in subjects of the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 1993;12:1558-1566.
22. Jurgens G., Koltringer P. Cerebrovascular disease and Lp(a): its role in atherosclerotic plaque formation and vessel wall elasticity of the carotid arteries. Chem Phys Lipid 1994;67/68:429-434.
23. Pedro-Botet J., Senti M., Auguet T. et al. Apolipoprotein(a) genetic polymorphism and serum lipoprotein(a) concentrations in patients with peripheral vascular disease. Atherosclerosis 1993;104:87-94.
24. Hoff H.F., Beck G.J., Skibinski C.I. et al Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery patients. Circulation 1988;77:1238-1244.
25. Hearn J.A., Donohue B.C., Ba'albaki H. et al. Usefulness of serum lipoprotein(a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1992;69:736-739.
26. Hoefler G., Harnoncourt F., Paschke E. et al. Lipoprotein(a): a risk factor for myocardial infarction. Arteriosclerosis 1988;8:398-401.
27. Durrington P.N., Ishola M., Hunt L. et al. Apolipoproteins (a), AI, and B and parental history in men with early onset ischaemic heart disease. Lancet 1988; i: 1070-1073.
28. Betteridge D.J., Gibson M. Effect of rosuvastatin on LDL-C and CRP levels in patients with type 2 diabetes: results of ANDROMEDA study. Atherosclerosis 2004;5:Suppl:107-108.
29. Harrison D.G., Armstrong M.L., Freiman P.C., Heistad D.D. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest 1987;80:1808-1811.
30. Tamai O., Matsuoka H., Itabe H. et al. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997;95:76-82.
31. Shepherd J., Cobbe S.M., Ford I. et al. for the West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
32. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
33. Treasure C.B., Klein J.L., Weintraub W.S. et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-487.
34. Masumoto A., Hirooka Y., Hironaga K. et al. Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin). Am J Cardiol 2001;88:1291-1294.
35. Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomised controlled trial. JAMA 2001;285:1711-1718.
36. Vaughan C.J., Gotto A.M., Basson C. T. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000;35:1-10.
37. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature 1990;343:425-430.
38. Ridley A.J. Rho family proteins: coordinating cell responses. Trends Cell Biol 2001;11:471-477.
39. Amano M., Fukata Y., Kaibuchi K. Regulation and functions of Rho-associated kinase. Exp Cell Res 2000;261:44-51.
40. Strey A., Janning A., Barth H., Gerke V. Endothelial Rho signaling is required for monocyte transendothelial migration. FEBS Lett 2002;517:261-266.
41. Worthylake R.A., Lemoine S., Watson J.M., Burridge K. RhoA is required for monocyte tail retraction during transendothelial migration. J Cell Biol 2001;154:147-160.